No Detail Found!

Safety and Efficacy of Zoledronic Acid in children with Osteogenesis Imperfecta

Author(s)
Maira Riaz Department of Endocrine and Diabetes, National Institute of Child Health,Karachi,Pakistan
Shahnila Hafeez Department of Endocrine and Diabetes, National Institute of Child Health,Karachi,Pakistan
Mohsina Noor Ibrahim Department of Endocrine and Diabetes, National Institute of Child Health,Karachi,Pakistan
Zubair Ahmed Khoso Department of Endocrine and Diabetes, National Institute of Child Health,Karachi,Pakistan
Taj Muhammad Laghari Department of Endocrine and Diabetes, National Institute of Child Health,Karachi,Pakistan
Syed Jamal Raza Department of Endocrine and Diabetes, National Institute of Child Health,Karachi,Pakistan
Abstract
Objective: To evaluate the e cacy and safety of zoledronic acid in children with osteogenesis imperfecta (OI). Study Design: Descriptive Study. Place and Duration of Study: National Institute of Child Health, Department of Endocrine and Diabetes, Karachi, Pakistan, from January 2011 to December 2020. Methodology: Children, with OI registered for the treatment, were included. Zoledronic acid was given to them by intravenous infusion over 30 minutes with a dose of 0.05 mg/Kg/day for a median duration of 60 (24-96) months. To ensure safety, patients were kept for 24 hours after dose administration to monitor any short-term side e ects. The patients were assessed after every 3-6 months for frequency of fracture, bone pain, and BMD. Result: Out of 82 children [40 females (48.8%) and 42 males (51.2%)], 11 patients (13.4%) had fever and 2 patients (2.4%) had u-like illness. No other side e ects were observed. The annual fracture rate decreased overall from 2.8±1.5 to 0.2±0.5 (Â0.001) in both males (2.6±1.3 to 0.1±0.4) and females (3.1±1.7 to 0.2±0.6). Z-score on DEXA scan showed improvement in BMD overall (-3.9±2.0 to 2.2 ±1.7), in males (-3.7±1.9 to -2.1±1.7) and in females (4.1±2.1 to -2.3±1.8). There were no other long-term side e ects like ocular problems, osteonecrosis of the jaw, and delayed healing of the fractures. Conclusion: Zoledronate use in children is associated with minimal short-term and long-term side e ects with a signi cant improvement in BMD and decline in fracture rate.
Publication Details
Page(s) 1165-1169
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 32, Issue: 9, Year: 2022

Request the full text from PASTIC

Keywords
Bone mineral density (BMD), DEXA scan, Osteogenesis imperfecta (OI), Bisphosphonates (BPs)
0

Citations

0

Downloads

71

Views